{"title": "Genomic and transcriptomic features of response to atezolizumab plus bevacizumab in advanced renal cell carcinoma (IMmotion151)", "doi": "10.1038/s41591-019-0654-5", "journal": "Nature Medicine", "year": 2019, "full_text_url": "https://www.nature.com/articles/s41591-019-0654-5", "tables_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0654-5/MediaObjects/41591_2019_654_MOESM1_ESM.pdf", "data_url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120622"}
{"title": "Biomarker analysis of CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma", "doi": "10.1038/s41591-022-01713-0", "journal": "Nature Medicine", "year": 2022, "full_text_url": "https://www.nature.com/articles/s41591-022-01713-0", "tables_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01713-0/MediaObjects/41591_2022_1713_MOESM1_ESM.pdf", "data_url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202964"}
{"title": "Biomarker analysis of CLEAR: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma", "doi": "10.1038/s41591-023-02513-2", "journal": "Nature Medicine", "year": 2023, "full_text_url": "https://www.nature.com/articles/s41591-023-02513-2", "tables_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-023-02513-2/MediaObjects/41591_2023_2513_MOESM1_ESM.pdf", "data_url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE210356"}
{"title": "Biomarker analysis of JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma", "doi": "10.1038/s41591-020-0784-5", "journal": "Nature Medicine", "year": 2020, "full_text_url": "https://www.nature.com/articles/s41591-020-0784-5", "tables_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-020-0784-5/MediaObjects/41591_2020_784_MOESM1_ESM.pdf", "data_url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150997"}
